An informatics workflow (Figure 1) was developed and applied to study the network pharmacology of BCR-ABL inhibitors, based on methods developed by Hajjo et al. [9,10,11,12], to formulate testable hypotheses regarding non-cancer indications and polypharmacological mechanisms. Here, ABL1 is linked to cancer.